Cat. No. 3599
Alternative Name: Mubritinib
Chemical Name: 1-[4-[4-[[2-[(1E)-2-[4-(trifluorome
Biological ActivityPotent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Spector et al (2007) Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 9 205.
Nagasawa et al (2006) Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int.J.Urol. 13 585.
Sridhar et al (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 4 397. PMID: 12850190.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses TAK 165 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: TAK 165, supplier, Potent, selective, ErbB2, inhibitors, inhibits, Epidermal, Growth, Factor, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, TAK165, Tocris Bioscience, EGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.